Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: Disappointment or hope?

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 2-3

  Laurent, Stéphane ^a,b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAGLUTRIL; DIHYDROPYRIDINE; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; PLACEBO; ASPARTIC PROTEINASE; BENZAZEPINE DERIVATIVE; ENDOTHELIN-CONVERTING ENZYME; METALLOPROTEINASE;

HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; ALBUMINURIA; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE;

ALBUMINURIA; ASPARTIC ACID ENDOPEPTIDASES; BENZAZEPINES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN;

EID: 84882655346     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70036-6     Document Type: Letter

References (10)

1. Mancia G, de Backer G, Cifkova R, et al. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH). J Hypertens 2007, 25:1105-1187.
2. Kim JA, Montagnani M, Koh KK, Quon MJ Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
3. Laurent S, Schlaich M, Esler M New drugs, procedure, and devices for hypertension. Lancet 2012, 380:591-600.
4. Corti R, Burnett JC, Rouleau JL, Ruschitzka F, Lüscher TF Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?. Circulation 2001, 104:1856-1862.
5. Dive V, Chang CF, Yiotakis A, Sturrock ED Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality?. Curr Pharm Des 2009, 15:3606-3621.
6. Daull P, Jeng AY, Battistini B Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007, 50:247-256.
7. Kalk P, Sharkovska Y, Kashina E, et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 2011, 57:755-763.
8. Remuzzi G, Perico N, Benigni A New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002, 1:986-1001.
9. Zoja C, Cattaneo S, Fiordaliso F, et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 2011, 301:F1114-F1123.
10. Parvanova A, van der Meer I, Ililev I, et al. Lancet Diabetes Endocrinol 2013, for the Daglutril in Diabetic Nephropathy Study Group, published online June 13, 2013. http://dx.doi.org/10.1016/S2213-8587(13)70029-9.